GUANZE MEDICAL (02427) has announced its financial results for the six-month period ended 30 June 2026, revealing a challenging first half that saw the company shift from profitability to a net loss.

During the reporting period, the group generated revenue of RMB 28.432 million, reflecting a decrease of 10.75% compared to the same period last year. The company recorded a loss attributable to shareholders of RMB 38.804 million, marking a sharp reversal from the profit achieved in the corresponding period of the previous year.

Basic loss per share for the interim period stood at RMB 0.041. According to the company, the decline in total revenue was primarily driven by reduced income from the sales of medical imaging software.

Despite the downturn in top-line performance and the swing to a loss, the management has not provided any specific guidance or strategic updates within the announcement.